Xu Rui-Hua,Wang Feng,Wei Xiao-Li,et al.Tumor mutational burden identifies chemorefractory gastric cancer with overall survival advantage after receiving toripalimab, a PD-1 antibody[J].JOURNAL OF CLINICAL ONCOLOGY.2019,37(15):doi:10.1200/JCO.2019.37.15_suppl.4021.
APA:
Xu, Rui-Hua,Wang, Feng,Wei, Xiao-Li,Wang, Fenghua,Xu, Nong...&Yao, Sheng.(2019).Tumor mutational burden identifies chemorefractory gastric cancer with overall survival advantage after receiving toripalimab, a PD-1 antibody.JOURNAL OF CLINICAL ONCOLOGY,37,(15)
MLA:
Xu, Rui-Hua,et al."Tumor mutational burden identifies chemorefractory gastric cancer with overall survival advantage after receiving toripalimab, a PD-1 antibody".JOURNAL OF CLINICAL ONCOLOGY 37..15(2019)